Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of SpikoGen Vaccine in Adults
NCT05005559Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SpikoGen in coronavirus disease 2019 (COVID-19), sponsored by CinnaGen. Started Aug 2021; status: completed.
02
Drugs
SpikoGen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05005559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005559.